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CHAPTER 12 
Recent Advances in Hepatic Transplantation at 
the University of Pittsburgh 
Kareem Abu-Elmagd, Oscar Bronsther, Ashok Jain, William Irish, Hector Ramos, 
/gnazio R. Marino, Forrest Dodson, Rick Selby, Howard Doyle, Hlroyuki 
Furukawa. Timothy Gayowski, Bakr Nour, Jorge Reyes, George Mazariegos, 
Antonio Pinna, Abdul Rao, Paulo Fontes, Adrian Casavil/a, Nicolas Jabbour, 
Wallace Marsh, Juan Madariaga, Anthony J. Demetris, Andress Tzakis, 
Satoru Todo, Shun Iwatsuki, John J. Fung, and Thomas E. StarzJ 
University of Pittsburgh Medical Center 
Pittsburgh Transolant Institute 
Pittsburgn. Pennsylvania 
We recently achieved 4 malar advances In clinical 
'leoatlc transplantation at our center first. the Introduc-
':on and demonstration of the suoenor therapeutic index 
ct the new ImmunosuppreSSive drug FK 506; second. 
ihe feaSibility (With the aid of thiS drug) of combined liver-
,nlestlnal and mulllVlsceral transOlantatlOn for oatlents WIth 
'1epatolntestlnal failure; third. 2 attemots at hepatiC 
xenotranSPlantatlon: and fourth. t:eglnnlng attempts to 
,nduce aonor·soeclflc nonreactlVlty wllh adluvant bone 
marrow more rapidly. These studies Will be addressed 
separately because of the unique deSign of each and 
the heterogeneity of the enrolled patient population. The 
survival curves for both patients and grafts were esti-
mated by the Kaplan-Meier (product-limit) method and 
the comparison among the different cohorts Within each 
population was done by the generalized Wilcoxon 
(Breslow) test. 
CLINICAL EVOLUTION OF FK506: 4 YEARS EXPERIENCE 
: ,nce Its c,scoverv In 1983 and before ItS Initial Cllnl-
:11 use In Feorjarv of 1989. the novel Immunosuppres-
ve aruq FK506 underwent extensive In·vltro and am-
"';11 stUdies (1 21. It was first used to salvage liver ai-
,)qratts that were failing because of releCtlOn despite 
~:ate-ol·the·an treatment With conventional Immunosup-
~ reSSlon 131. 7"'1e encouraging resuits of tna rescue tnal 
.j \ lustlfled !t1e evaluation ot FK506 as the pnmary 1m-
'''unosuooressant for our liver allograft rectplents (5). 
qather than summarizing our overall clinical experience 
.vltn neoatle tranSPlantation. we Will focus on the thera-
.:eutlc ertlcac'. at FK506 among pnmary liver allograft 
'f'CIDlents. -:-re blocharactenSIiCS. pharmaCOkinetics. 
Jna methOdS of assay ot FK506 are fully descnbed else-
Nnere 16-101. 
MATERIALS AND METHODS 
Patient Population 
From August 18. 1989 through August 1. 1993. 
1 .153 consecutive patients underwent pnmary liver trans-
plantation and received FK506 as the primary Immuno-
suppressive agent. The patient charactenstics are sum-
manzed in Table 1. Of the 1.153 reCIpients. 84% were 
adults and 16% were children. The mean age was 51 ± 12 
years (range: 18-76) for adults and 6t6 years (range:0.2-
17.8) tor children. Of the adult patients 251 (26%) were 
over 60 years of age. The indications for liver trans-
plantatiOn based upon the histopathOlogiC diagnOSIs of 
the native liver disease are given In Table 2. Parenchy· 
C:lnlCal TranSPlants 1993. TerasaKJ and Cecka. Eds_ UCLA Tissue TYPing Laboratory. Los Angeles. Calltornla 
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Immunosuppression 
From the outset. FK506 was used for all patients. 
The early phase of the study was carneo out dunng the 
leamlng curve In which the dally Inducllon doses were 2 
or 3 times greater than those currently recommended (8, 
13-15). Our present policy IS to give FK506 inlttally intra-
venously as a continuous Infusion at a dose of 0.05 mg/ 
kg/day. The conversion from Intravenous to oral ttlerapy 
IS usually made without any ovenao With a starting oral 
dose of 0.1·0.15 mglkg every 12 hours. Dose adjust-
ments dunng both the Intravenous or the oral administra-
tion of the drug were dictated by FK506 plasma trough 
:evels. documentation of relectlon. cresence of adverse 
drug reactions With special empnasls 01 nePhrotOXICity 
and neurotoxIcity. eVidence of Infecuon. and funCtlonal 
status at the gran (13). 
mmedlatelv after graft repenL:Slon. one gram of 
"iemvlprednlsolone was administered Intravenously. A 
<1allv dose ot 20 mg of prednzsone was started and re-
JuCed In 2 or 4 weeks In the aosence 01 relectlon. There-
atter. prednzsone was weaned and IreQuently discontin-
ued. The first 63 patients and mose wno had a strong 
;Josilive CytotOXIC crossmatch were given a 5-day steroid 
:aper begin nina at 200 mglday for the hrst postoperatIVe 
Jav With redUC:lon ot 40 mglday unlll 20 mglday was 
'eacned on me Sixth dav. SterOid doses were scaled 
;own tor cnlldren. Prostaglandin E. :;::roson") was added 
. J :ne ImmunosClPpresslve cocktail of some patients dur-
'1() me first postoperative week' 1 6) A low dose of 
izatnlopnne 10.5·2 mglkgldavI was Olven to about 10% 
~f Ine patients at some time dunnq :ne postoperative 
;.;enOd. 
Nhen relectlon occurred. It was treated With an In-
:reased maintenance dose 01 ch~MS and a one gram 
:COluS ot either methvlpredniSOlone or nvdrocontsone. A 
sterOid recycle ana/or a 5-dav course 01 OKT, (5-10 mg/ 
Table 4. Causes of death after pnmary 
liver transplantation under FK506 
theraoy. 
n (%) 
;:Culmlnant InlectlOn 99 (9) 
Graft failure 24 (2) 
~""allgnancv 21 (2) 
CardiovaSCUlar ~U (1) 
Others ol6 (oll 
Unknown 25 12) 
-otal 233 (201 
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Figure 1. The Kaplan-Meier 
(actuarial) patient and graft survival for 
primary liver allograft recipients who 
received FK506 as the primary 
immunosuppressive drug therapy. 
day) was given to patients With moderate to severe re-
Jection episodes. 
RESULTS 
Total Population 
Of the 1 . 153 liver reCipients. 233 (20%) patients have 
died for reasons summanzed in Table 4. With a mean (± 
SO) follow-up of 22± 15 months (range: 3-49). the overall 
patient actuanal survival rates were 90%.87%.83%. and 
75%. at 3. 6. 12 and 48 months. respectively (Fig. 1), 
With a total of 1.308 liver allografts. 155 (13%) failed. 
Rejection was the cause of failure of only 6 grafts (4%). 
The overall graft survlvat was 81 %. 78%. 74%. and 65% 
at 3.6.12. and 48 months respectively (Fig. 1). The dif-
ference between patient and graft survival emphaSizes 
the survival benefit of retransplantallan. 
Randomized versus Nonrandomized 
Groups 
As exoected. the highly selected randomized group 
(n=79) had slgnlficantty bener pauent (p=0.006) and graft 
(p=O.OOl) survival compared With the nonranaamlzed 
patients (n=533) who were excluded from the random-
IZed study (Rg. 2). The 2-year patient survival was 91"10 
versus 76% With a gratt sutvlval rate af 88% versus 67"1... 
The survival difference between the 2 groups reilects the 
cumulative aetnmental effect of the exclUSion cntena that 
were used for randomizatiOn. 
100 
_80 
~ 
-
160 
~ 
= (I) 40 
-c: G) 
:; 20 . 
Il. 
o 
~ \. .. 
'- --- .. 
-
.. 
----KK:K~ 
-
UNOS STATUS 
- [1+2J (n=197) 
-
3 (n=442) 
4 (n=384) 
- 5 (n=130) 
o 6 12 18 24 30 36 42 48 54 
Months Aftar Transplantation 
Figure 4. Patient survival after liver 
transplantation stratified according to the 
medical urgency for surgery as defined 
by the standard criteria of the Umted 
Network for Organ Shanng (UNOS). 
Primary Liver Disease 
Patients With either parenchymal or cnolestatlc liver 
disease had similar and high long·lerm survival rates 
Nlth FK506·based Immunosuppression (Fig. 5). The 
~ecent achievement of a hlgn posttransPlant sUrYIval rate 
'82% at 12 months) for patients with fulminant hepatiC 
'.lilure IS attributed to the current monltonnq at Intrac· 
,>rebral bloOd flow and prevention 01 excess Intracranial 
~ressure In aaaltion to the therapeutic aavantage at 
;:K506. As exoected. recIpients With a penoperatlve al· 
.1qnosls of pnmary hepatiC malignancv naa the lowest 
,)ng·term survival; 72% at one year and 59% at 2 years. 
-he common cause of patients death was tumor recur-
~ence deSPite the utilization of pretransClant Intra-arte· 
':31 Chemotherapy In some ot these patients with or With-
Jut posttransPlant systemic ChemOtheraoy. 
Recurrence of Viral B Hepatitis 
In a series of 78 consecutive oallents With hepalltls 
:3 VIral (HBV)·related diseases. 56% had disease recur· 
:ence With a median tallow-up of 24 monthS. Those 
NhO have higher levels at HBV reOllcallons (n=8\ as as· 
sessed by the presence of HBe anlJgen POSitiVity. expe-
':encea a higher rate of disease recurrence 188%). ana 
.'1alf of them (n=4) died of recurrent hepalltls. The use 
at hepalltls B immune globulin did not prevent disease 
'ecurrence but may have delayea Its clinical onset. 
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Figure 5. Survival of FK506 primary 
liver allograft recipients stratified 
according to the pathology of the 
primary liver disease. 
Retransplantation 
The need for graft replacement was Significantly re-
duced With the use of FK506 (12%). PatIent survival af· 
ter retransplantatlon was 75% at 3 months and 54% at 2 
years (Fig. 6). 
Rejection 
The InCidence and treatment of liver allograft reJec· 
lion under FK506 has been reported elsewhere (17). In 
summary. greater than 50% of the liver recIpients were 
rejection free and nearly half of them were sterOid free 
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Figure 6. The actuarial patient survival 
after retransplantation. 
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Figure 7. SurvIval of the combined liver-intestinal and multivisceral recipients. 
A) all 27 patients; B) according to procedure. 
The management strategy tor tnese unique liver reo 
crplents IS descrloed comprehenSively In our recent 
;JuOllcatlons 131. 32l. The basIc :mmunosuppresslve 
Jruq lt1erapy was FKS06 In addition to sterOids and pros-
!:Jqlandln E" -'ugmented ImmunosuppreSSion was Ini-
':ateo aWlnq re:ectlon epISOdes. based upon seventy. A 
.lerala cOlus.'Jas given and FK506 aosage was In-
':eased Wnp.n :r-.:s was POSSible WllnOUt nepnrotoxlcltv. 
., sterOID recyee lor 5 days anOlor a (··jay course at 
=Ki . .vere oaCKUp oPlions. 
RESULTS 
Patient Survival 
Dunnq potential follow-ups at 6-39 months and as 
:1 OctOber 1993.9 (33%1 ot the 27 oatlents died: 8121 
-:omolnea liver ana Intestine. and 116 multlvlsceral. The 
-:auses 01 the :3 deathS were either tecnnlcal compllca-
:.ons I n=31. opoortunlstlc In(ectlons (n=2). uncontrolled 
~rall rerectlon In=2), or diSSeminated oosttransplant 
vmonoorollterallve disease t PTLD) (n=2). 
SIX at the 8 mortalities atter combined liver and In-
:estlnal transPlantation were of children. Erltenc ana/or 
::;illarv leaKS were responslOle tor 3 deathS. The other 3 
.'Jere caused bv resPlratorv syncvtlal Viral pneumonia. 
"etractorv acute releCtiOn. or PTlD (one examOle eaenl. 
Cne at the 2 :iver-Intestlne adult reclOlents died of 
hepatorenal failure combined With chrOniC relection and 
the other succumbed to disseminated COCCidiomycosis. 
The only death in the mulllvisceral senes was caused 
by PTLD which was diagnosed at autopsy 49 days 
posttransplantation. 
The actuanal survival rate tor the 27 patients at 3, 
6. 12. and 24 months was 82%. 79%. 74%. and 69%, 
respectively (Fig. 7). The mean tollow-up penod was 
1 6± 12 months for liver plus Intestine and 11:!:8 months 
for multlvisceral reCIpients. At 3 months. the survival 
rate for the combined liver-Intestine reCIpients was 81 % 
and 86% for the multivisceral recIpients. At one year 
follOWing transplantation. these estimates were 71 % and 
86%. respectively. At 2 years. the actuanal survival rate 
was 65"10 for the combined liver intestinal reCIpients and 
86"10 for those who received multlvlsceral grafts. 
Graft Survival 
The estimated actuanal survival tor all of the grafts 
in=28) was 76%. 76%. 71%. and 67% at 3. 6. 12. and 
24 monthS. respectively (Fig. 8). Grall survival was 
higher dUring the entire follow·up penod for the 
multlVISceral cases compared to those With combined 
llver-Intesllne. All but one graft was lost due to patient's 
death. The only graft removed at reoperallon was a 
liver-intestine transplanted to a child across a strong 
positive CytOtOXIC cross matCh. Although graft removal 
CLINICAL XENOTRANSPLANTATION 
MATERIALS AND METHODS 
In June 1992 and January 1993. 2 male patients 
aged 3S and 62 years. With end-stage liver disease due 
to chromc B viral active hepatitis had their CIrrhOtiC livers 
replaced with baboon livers (33. 34). These eHorts were 
prompted by the worldwide shortage of donor organs and 
by eVidence that baboon livers would be resistant to the 
hepatitis B ViruS that reinfects most hepatic allografts_ 
ExtenSive Infectious surveillance was performed for both 
donors. Both recipients had ABO-compatlble gratts. The 
conventIOnal Iymphocytotoxlc crossmatch of both reCipi-
ent sera to their donor lymphocytes was pOSitIVe In both 
cases but negative after dlthlothreltol treatment. A full 
descnptlon of oath donors and reCIPients has been pub-
lished elsewnere (33. 34). 
The surgical techmques were aaaPted from hepatlc 
allotransplantation (35). Althougn rne baboon donors 
were large. their oody weights were only 40% of the re-
CIpients. necessitating the so·called piggyback opera-
tion which leaves the recipient vena cava Intact. The 
surgical proceaure In both cases was sallsfactory Ini-
tially and dunng the postoperative course. there was ra-
diOlogiC and histopathologic eVidence of liver regenera-
tion and Increased graft vOlume (33. 34). 
The Immunosuppressive COCKtail used for preven-
:Ion and contrOl of relectlon at the 2 haoallc xenogratts 
.vas made Ov F"::S06. sterOids. C'/C:oOhOsonamlde. and 
~rostaqlandln E. Doses ana routes 01 aamlnlstratlon 
Jre snown In F'gures 9 ana 10. Detailed descnPtlons of 
:he ImmunosuopreSSlve meraov and drug Olood levels 
.vere recentlv reported elsewnere 134). 
RESULTS 
The I,rst raClplent aWOKe oromotlv tram anesthe-
Sia, resumea diet and amoulatlon. and was Jaundice-
'ree tor most 01 the 70 days of survival. However. the 
,;anallcular enzymes were high from the secona week 
onward 1 Fig. 9) Two months alter transOlantatlon, 
cterus Iinaliv cevelooed ana It was ascnoea to partial 
obstruCtion 01 the reconstructed bile duct. At autopsy. 
:ne entire oillarv tract was 1IIIed With InsPissated bile. 
and most of the CIliary ducts were denuded of eplthe-
:Ium. In contrast. the secona pallent remaltled Ictenc 
(Fig. 101 and comatose atter the operation. The xe-
nograft had the same cholestatic picture as the first one 
despite adequate biliary anastomosIs. In both patients. 
the jaundice was not particularly responSive to aug-
mented immunosuppression with steroid boluses and 
increased maintenance doses of prednisone. 
Hypoalbuminemia was evident in both patients «2 gm'%) 
in spite of other adequate synthetic function including 
prothrombin time (34). Renal failure was inevitable in 
both patients. It developed in the first recipient after 21 
days. whereas the second patient became anuric imme-
diately after the transplantation. 
Although the cause ot death in both cases was mul· 
tifactorial. the first recipient succumbed to ruptured in-
tracerebral mycotic aneurysm due to disseminated . 
aspergillosis and the second died of pentonltis second· . 
ary to an anastomotic leak at the jejunojejunostomy of 
the Roux-y biliary reconstruction (34). Meanwhile. nei· 
ther of the 2 hepatiC xenogratts proVided adequate func-
tion despite the absence of significant histopathologic 
abnormalities. Immunoperoxldase staining revealed no 
evidence of reinfection of the hepatic allograft with HBV 
in either case. 
There was little histopathologic eVidence of humoral 
or cellular relectlon of these 2 liver xenografts. Only 
one 01 the 5 biopSies obtained from the lirst patient (post-
operative day 12) had a mild focal cellular rejection and 
none of the 7 biOpsy samples taken from the second 
patient showed any definite eVidence of cellular relec-
tlon by the conventional cmena used for hepatiC al-
lografts. The hepatiC xenogratt of both patients was 
entirely free of any histopathOlogiC eVidence of artentis 
during the entire postoperative course. However. 
sludglng as well as the presence of polymorPhonuclear 
leukocytes was seen In the slnusolds of the xenogratts 
Immediately after reperluSlon. compatible With the di-
agnosIs 01 an aborted hyperacute relection (36). Dur-
Ing the first 2 weeks after transplantation, the total 
complement was depleted while complements CJ • C,. 
and C1 became undetectable. DUring thiS time. there 
was binding of IgM and IgG in the gratts With appear-
ance of CI rculatlng Immune complexes (36). After 10 
days. the complement system settled down Outlfrevers-
Ible damage may have been done which could be re-
flected In the form of diffuse tine mlcrosteatoslS ot the 
gratt. 
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Figure 10. Clinical course of the second liver xenograft 
(baboon-fa-human) recipient. 
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After special staining procedures (immunostalning 
or sex identification after fluorescence in situ hybridiza-
tion [FISH]). it was possible to determine If the individual 
cells had come from the organ donor. the reCIpient's 
own body. or both. In confirmatory Investigations. the 
donor and recipient contnbutions to any specimen could 
be separated by polymerase chain reaCIJon ("DNA fin-
gerprinting") techniques. 
From these analyses and from supporting labora-
tory experiments in animals it was clear that Within min-
utes after restoring the blood supply of any transplant. 
myriads of sessile. but potentially migratory leukocytes 
that are part of the normal structure of all organs (pas-
senger leukocytes). lett the graft and migrated ubiqui-
tously. while being replaced in the transplant by Similar 
recipient Immunocytes under the cover of immunosup-
pressive drugs (Fig. 11). In this new context. the drugs 
could be viewed as traffic directors. ailowmg movement 
of the wMe cells to and from the graft but preventing 
the Immune oestructlon that IS the normal purpose of 
thiS traffic. 
It is not known yet how the 2 sets of white cells - a 
small population from the donated organ and a large one 
that IS. in essence. the entire recipient Immune system of 
the pauent - reach an ImmunOlogiC "truce: However. 
thiS IS so complete In some cases that Immunosuppres-
sion can be stooped. particularly aller hver transplanta-
tion but less constantly With other organs. Such a stable 
~lologlC state can be Induced more eaSily by the liver 
:han by other transplanted organs because of the liver's 
hlgner content of the CntlCal leukocytes that apparently 
Included plun·potent stem cells. 
We have postulated that the prevIously unrecog-
nized migration from organ allografts of donor leukocytes 
and thelf ubiqUitous persistence In reCIpient tissues is 
the seminal explanation for allograft acceptance and the 
first stage In the development of donor specific 
nonreactlvlty (tolerance) (37·41). With thiS hypotheSIS. 
we unoertook tM augmentation of the donor leukocyte 
load With a penoperatlve tnfuslon of nondepleted bone 
marrow tn 16 noncondltloned reCIpients of livers (n=6). 
kidneys (n=9\. and a heart tnCludlng 3 diabetics who 
also were given pancreatic Islets. All 16 have good or-
gan transplant function ana eaSily detectable blood 
macrochlmensm (1·15%) aller one to 12 postoperative 
monthS. None nave had Significant GIIHD. It IS too earty 
to attempt disconunuatlon therapy. but senal In'lIltro test-
Ing haS revealed a pronounCed trend to donor·speclfic 
nonreacttvlty (tolerance). 
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DISCUSSION 
During the last decade. survival after liver transplan-
tation has improved significantly with advanced medical 
technology, greater surgical experience, better organ 
preservation. and new, mare effective immunosuppres-
sive agents. The recent introduction of FK506 has fur-
ther improved the survival and quality-of-life advantage 
of hepatic transplantation when compared with our pre-
vious experience (42). A summary of the worldwide ex-
perience with FK506 was presented during the 1991 First 
Intemational Congress on FK506 and has been published 
elsewhere (43); the drug recently completed its "fasttracK'" 
journey through the FDA. 
With the evolution of a patent immunosuppressive 
drug like FK506. further improvement in patient and graft 
survival may only be possible by perfecting the surgical • 
techniques with early detection and prompt correction of 
technically flawed operations (44). However. even with a 
perfect operation, recurrence of the primary liver disease 
is a maJor threat to graft and patient survival after liver 
transplantation. It is well known that candidates with ei-
ther active VIral hepatitis and/or liver malignancy remain 
at high nsk of disease recurrence. The results of our 
cumulative expenence with the prophylactiC or therapeutic 
use of antiViral agents have been unsallsfactory (45-47). 
A role may emerge for thymosln. the new 
Immunomodulator for preventton or treatment of recur-
rent VIral hepatitis among liver allograft reCIpients. The 
survival benefit of our current protocol of treattng liver 
reCipients carrying the penoperatlve diagnOSIs of pnmary 
liver malignancy With intra-artenal andlor systemic che-
motherapy have yet to be determined. but the early re-
sults are less encouraging than hoped for. 
The survival outcome atter liver transplantation is 
profoundly Influenced by the reCIpient's conaltlon at the 
time of surgery, particularly If the preterminal or termi-
nal stages (UNOs 4 and 5) are reached. The best post-
operative 2-year SUrvival rate was In the lowest risk 
UNOs 1. 2. and 3 pahents (83% combined) and the 
worst results were those In UNOs 4 and 5 (76% com-
bined). The continuing shonage 01 organs for trans-
plantation compounded by the current organ allocatiOn 
policies In the United States continues to Imoose a sig-
nificant mortality among the high-fiSk categories while 
awaiting for liver replacement (48). 
The recent achievement of satisfactory long-term 
survival of patients treated With combined Iiver-fnlestJ-
nal and mutllvisceral transplantatiOn IS lustlficatlon for 
,... 
-~ 
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